Rx for Biotech

In this podcast episode, our guest, Karoline Eastman, SVP of Customer Experience and Strategy Lead at Pixacore, discusses new digital trends for pharma in 2023 and how to improve HCP and patient customer engagement.

Our guest in this episode is Cove Therapeutics CEO, Niren Shah, who discusses the pitfalls of current viral vector based gene therapies and shares how Cove's next generation non-viral gene delivery platform overcomes many of the challenges of viral vectors.

There are many hurdles to streamlined, cost-effective manufacturing of cell and gene therapy products. To help address this, the Alliance for Regenerative Medicine published A-Cell, a case-based guidebook to help drug developers incorporate Quality by Design (QbD) principles into cell-based therapy CMC programs. A-Cell builds on previous QbD efforts that were applied to the manufacturing of monocl...

There are many hurdles to streamlined, cost-effective manufacturing of cell and gene therapy products. To help address this, the Alliance for Regenerative Medicine published A-Cell, a case-based guidebook to help drug developers incorporate Quality by Design (QbD) principles into cell-based therapy CMC programs. A-Cell builds on previous QbD efforts that were applied to the manufacturing of monocl...

The Inflation Reduction Act was signed into law in August 2022 and is one of the most significant pieces of healthcare reform since the Affordable Care Act. In this episode, learn more about how the new policy will impact R&D portfolio decision making and new product development strategies.

The FDA’s Office of Tissues and Advanced Therapies hosted their first virtual town hall to answer industry questions related to gene therapy chemistry, manufacturing, and controls. In this episode, we unpack what happened at the town hall and provide a brief overview of the key insights and guidance from the agency for those developing gene therapies.

Twice a year, the Alliance for Regenerative Medicine (ARM) surveys the cell and gene therapy landscape to advance the field and provide an update to their members, stakeholders, and the public. In this podcast, Stephen Majors, Senior Director of Public Affairs, reviews key insights from ARM's updated cell and gene therapy sector report for the first half of 2022. ARM is the leading international a...

In this episode, Jan Hannon and Lisa Hefner from BluPrint Oncology dig deeper into scientific and medical communications and how health care provider education has evolved in the post-COVID pandemic era.

In this episode, Paul Callahan, President and Founder of CDT Pharma Strategies discusses market access, trade and distribution best practices for novel therapeutics.

In this episode, Dr. Ramanathan discusses best practices in Pharmaceutical, Biotechnology, and Academic partnerships, alliance management, and innovation.

The biopharma ecosystem is devoting significant resources to develop novel cell and gene therapies to treat cancer. In this episode of "Rx for Biotech", Chris Dokomajilar discusses trends in Biotechnology investment, licensing and partnering landscape and provides an outlook on what to expect for the remainder of 2022.

Our guest in this episode is Dr. Andrew Garst. We discuss the technology behind powerful new genome editing tools that are driving new therapies to treat genomic and inherited human diseases.

During this episode, we explore the key opportunities and challenges with the future commercialization of innovative personalized therapies with our guest, Michael Amoroso, a leader in the cell and gene therapy industry.

In this episode, Dr. Katie Graham reviews FDA regulatory review process for innovative new biotechnology and pharmaceutical products. Dr. Graham shares best practices in helping emerging biotechnology companies accelerate their organizational launch readiness.